Article info

Download PDFPDF

Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Free
  1. James Raftery, Wessex Institute for Health R&D, Mailpoint 728, Medical School, University of Southampton, Southampton SO16 7PX, UK; raftery{at}soton,.ac.uk
View Full Text

Citation

Raftery J, Clegg A, Jones J, et al
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness

Publication history

  • Accepted March 14, 2007
  • First published April 12, 2007.
Online issue publication 
August 20, 2007

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.